Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Confo Therapeutics: Drugging the Undruggable

Llama single-domain antibodies have found yet another application, one that Confo Therapeutics is fully exploiting. Ablynx is developing Nanobodie…


How to build a “European Amgen”

There are still very few large European biotech companies to compete with the Amgens and Gileads of the world.  Only a handful of European biotech…


Belgium vs Germany in the Life Sciences start-up championship

Germany is one of the leading industrial nations in the world and has 8x more inhabitants than Belgium. However, when it comes to investments in e…

POPULAR TAGS

Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities

Written by ALB on in the category news with the tags , , .


Confo Therapeutics announced today that it has received a €1 million grant from the Flemish Government through Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to support the development of new methods for screening libraries of small molecules for the discovery of new therapeutic candidates targeting G-protein coupled receptors (GPCRs), using the company’s proprietary conformation-sensitive single domain antibodies or Confobodies.

Commenting on the grant, Dr. Cedric Ververken, CEO, said: “Once again we are grateful for the financial support by VLAIO totaling €1 million over 16 months. The grant will support the continued development of our GPCR screening capabilities.”

Dr. Christel Menet, CSO, added: “The goal of this project is to develop unique proprietary Confobody-based screening technologies providing a ‘next generational’ improvement in performance over current GPCR screening approaches. These new methods will be highly complementary to our current Confoscreen assays and will thereby maximize our overall chance of success in discovering therapeutic candidates to previously ‘undruggable’ GPCRs.”

More information:
www.confotherapeutics.com

Read more about: , , .

RELATED ARTICLES
Confo Therapeutics: Drugging the Undruggable

Llama single-domain antibodies have found yet another application, one that Confo Therapeutics is fully exploiting. Ablynx is developing Nanobodie…


How to build a “European Amgen”

There are still very few large European biotech companies to compete with the Amgens and Gileads of the world.  Only a handful of European biotech…


Belgium vs Germany in the Life Sciences start-up championship

Germany is one of the leading industrial nations in the world and has 8x more inhabitants than Belgium. However, when it comes to investments in e…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

XpandInnovation V-Bio Ventures Janssen Turnstone UGent GSK Biowin Itera Life Science Flanders.bio KU Leuven

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.